Government Conducts On-Site Inspection of Sinseong Yakpum: "No Cases of Vaccination Exposed to Room Temperature"

[Image source=Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] On the 23rd, the government is conducting an on-site investigation of Sinseong Pharmaceutical, which caused the suspension of the national vaccination program by exposing influenza (flu) vaccines, which must be distributed refrigerated, to room temperature.

The Korea Disease Control and Prevention Agency (KDCA) stated in a reference material on the same day, "Currently, in cooperation with the Ministry of Food and Drug Safety and local governments, we are conducting an on-site investigation of Sinseong Pharmaceutical to verify the appropriateness of the distribution process and compliance with standards."

The KDCA is also checking the transportation structure to determine whether there are any issues in the usage process, such as the relationship between Sinseong Pharmaceutical and the consigned delivery company.

So far, it has been confirmed that there have been no cases of vaccinations administered using vaccines exposed to room temperature. According to the KDCA, vaccination status can be identified by medical institutions through the manufacturing numbers supplied by the company.

The KDCA has also ordered a suspension of delivery for 7 million doses (single vaccination units) of flu vaccines, excluding the quantities already supplied by Sinseong Pharmaceutical.

The government plans to collect the flu vaccines exposed to room temperature, verify their safety and efficacy, and if no issues are found, gradually resume vaccinations. However, at this point, it is difficult to determine whether these vaccines can be reused.

This content was produced with the assistance of AI translation services.